Antihormonal therapy in breast cancer and mTOR inhibitors

被引：1

作者：

Heudel, Pierre-Etienne ^{[1
]}

Tredan, Olivier ^{[1
]}

Ray-Coquard, Isabelle ^{[1
]}

Treilleux, Isabelle ^{[1
]}

Guastalla, Jean-Paul ^{[1
]}

Bachelot, Thomas ^{[1
]}

机构：

[1] Ctr Leon Berard, F-69008 Lyon, France

来源：

BULLETIN DU CANCER | 2011年 / 98卷 / 12期

关键词：

metastatic breast cancer; hormonotherapy; mTOR inhibitors; PHASE-II; TEMSIROLIMUS; EVEROLIMUS; TAMOXIFEN; LETROZOLE; RAD001; COMBINATION; RESISTANCE; ACTIVATION;

D O I：

10.1684/bdc.2011.1496

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hormonal dependence of breast cancer has been known for a long time, yet about half of breast cancers with estrogen receptor will not respond to antihormonal therapy. Now, we know that this resistance may be related to a dysfunction of the estrogen pathway, or that of growth factors and particularly the pathway of cell activation PI3K/Akt/mTOR. Prevention of these different mechanisms of resistance could involve combination therapies such as anti-estrogens (SERMs, aromatase inhibitors) with inhibitors of the activity of growth factors that are particularly temsirolimus and everolimus for the activation pathway cell PI3K/Akt/mTOR.

引用

页码：1431 / 1437

页数：7

共 28 条

[11] Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer [J].

Chan, S ;

Scheulen, ME ;

Johnston, S ;

Mross, K ;

Cardoso, F ;

Dittrich, C ;

Eiermann, W ;

Hess, D ;

Morant, R ;

Semiglazov, V ;

Borner, M ;

Salzberg, M ;

Ostapenko, V ;

Illiger, HJ ;

Behringer, D ;

Bardy-Bouxin, N ;

Boni, J ;

Kong, S ;

Cincotta, M ;

Moore, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5314-5322

[12]

Chow LWC, 2006, SABCS M

[13]

Clark AS, 2002, MOL CANCER THER, V1, P707

[14]

Coutte L, 2011, B CANC

[15] Molecular prognostic and predictive markers of breast cancer treatment [J].

de Cremoux, P. .

BULLETIN DU CANCER, 2010, 97 (11) :1297-1304

[16]

Debled M, 2011, B CANCER, V98, P655, DOI [10.1684/bdc.2011.1367, 10.1684/bdc.2011.1367.]

[17] Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity [J].

DeGraffenried, LA ;

Friedrichs, WE ;

Russell, DH ;

Donzis, EJ ;

Middleton, AK ;

Silva, JM ;

Roth, RA ;

Hidalgo, M .

CLINICAL CANCER RESEARCH, 2004, 10 (23) :8059-8067

[18] Topics in mTOR pathway and its inhibitors [J].

Dreyer, C. ;

Sablin, M. -P. ;

Faivre, S. ;

Raymond, E. .

BULLETIN DU CANCER, 2009, 96 (01) :87-94

[19] Is cancer mortality increasing in France? [J].

Hill, C ;

Jan, P ;

Doyon, F .

BRITISH JOURNAL OF CANCER, 2001, 85 (11) :1664-1666

[20]

Institut national de veille sanitaire, PROJ INC MORT CANC F

← 1 2 3 →